Member Info for Globetrotter184

Taverham, it is well that we forget about Porky. Mislead many investors. Don't miss him at all

Look forward to that Casper.

Aberystwyth as you so correctly quoted " potential best in class.....potential multi billion sales....potential better asset.. "
There is a chasm between potential and reality or certainty. Not even started clinical trials. So the price appreciation to the present SP of around 5p amply reflects this " potential". Many months away from having some tangible news. Willing to wait but i do not expect any fireworks for now. Coverage by analysts in my view is dire . Do not expect any guidance from BOD for now as realistically there is little else to report except what is already known. Still high risk/high return situation which is normal for this kind of AIM share and particularly in the biotech sector. I hold and will continue to hold Sareum but my expectations are a bit more down to earth. Certainly not de ramping.

Nothing is "easy" SPURS 312. I admire your enthusiasm but at the same time you are advocating another 10% down. Feet on the ground. We are at least 6 months away from any tangible news. Firm belief in the science but also accept that there are risks which are normal to the sector.

That i did Wilson 63, if you don't mind. Do i need your permission to stay on this BB.?

Exactly " waiting and seeing how much grass its been chewing" And here lies the market doubt amongst other factors. No progress reports from company. Complete silence which gives rise to negative vibes and speculation. Talk by CEO to grow company into a mid cap is futile unless you build momentum supported by facts.

BrentW1 the market knows something ordinary holders don't know. All this talk about shorters etc etc is peripheral. Market is heading towards valuing the company only for its cash at bank. Everything else is hazy and unclear and absolutely no sense of direction from the BOD. The CEO silence speaks volumes. He is also at a loss it seems. Novacyt is simply "another " diagnostic company as tens and tens of others. No market advantage and not in the good books of DHSC. Many other opportunities in the market.

Gunner the BOD will not comment on SP. This is AIM and expect wild fluctuations even on low volume. No prospect of takeover bid at this stage, way too early. We have to be patient and wait it out for next 6 months.

Moniman why should new CEO buy? Nothing attractive on the horizon no catalyst to revive SP. Out of favour with DHSC and no transparency as to future plans just generic chatter. The conspiracy theories on MM's have proven to be mostly unfounded. I was out last week. Will re enter if i see some tangible news which does not seem forthcoming. CEO will be able to buy, should he want to do so, at lower levels , at at this rate sub £2.

Pharmaguy the fall in SP is a reflection of the fact that no news is round the corner. Investors get cold feet and cash in when too optimistic projections fail to materialise. Expect price to drift for some months and bid/offer spread widening.

Mafuta investors who went in at much lower levels will want to take a profit. I would not consider selling at this stage but there are risks and nothing is a certainty. Delays will occur and setbacks for this kind of product is common.

Hi Brenda!!

Ade1234 you are being optimistic waiting for GBP 4. Lower it to 3 but i doubt even that level may be a big challenge in the present circumstances.

Govt in no hurry to resolve issue. Very low in its list of priorities. The SP is already showing signs of discounting this outcome.Nova is simply a company which is rapidly falling out of favour with investors and analysts. ODDO was right after all.

With investor confidence shattered and DHSC likely to be resolved in favour of Govt plus absolutely no vision for the future means that inevitably the SP will simply go south possibly under GBP 2. Great disappointment for investors. Selling off to greener pastures. Good luck to all.

Stoney You are not comparing like with like. Aurinia have a marketed drug while SARE has a promise of that. Poles apart. The big pharmas will more likely be interested in companies which already have a drug on the market . Notwithstanding willing more than willing to hold on to SAR as i firmly believe in the science behind it.

Stoney You are not comparing like with like. Aurinia have a marketed drug while SARE has a promise of that. Poles apart. The big pharmas will more likely be interested in companies which already have a drug on the market . Notwithstanding willing more than willing to hold on to SAR as i firmly believe in the science behind it.

No harm in dreaming Bluelight !!

Nothing more than a mirage, JCB. I said it before the price will languish around these levels with an easier bias. Too much doubt surrounding DHSC issue and no clarity as to level of sales. Nothing to excite the imagination of investors at the moment.For the time being the price will simply reflect cash at bank and nothing else. Occasional blips in the price will happen but unless backed up by real solid news the rally will be short lived. I am an LTH but still regret at having not been able to recognize last years price as an opportunity to at least half my holding. Was sheer greed on my part and only myself to blame.

I follow your line of reasoning Har Chris. Certainly hope that Graham's replacement will change the mentality to a winning one.